MRSA produces abscesses in 70-80% of community-associated cases and carries a 20-50% mortality rate in bacteremia. Nasal colonization precedes 80-90% of later infections. Data across clinical patterns, transmission rates, and control measures map the current extent of spread and response options.
Key Takeaways
- Skin infections present as abscesses in 70-80% of CA-MRSA cases
- In the United States, invasive MRSA infections decreased by 54% from 2005 to 2011, from 13.7 cases per 100,000 population to 6.6 cases per 100,000
- Universal decolonization with chlorhexidine + mupirocin reduces MRSA cultures by 37%
- Hospitalization for MRSA infections in US children increased 10-fold from 1999-2006
- Vancomycin minimum inhibitory concentration (MIC) creep to 2 mg/L seen in 25% US MRSA isolates 2006-2012
MRSA remains a persistent threat, with rates varying but staying high in healthcare settings.
Related reading
01 · Category
Clinical Features24 stats
01
Skin infections present as abscesses in 70-80% of CA-MRSA cases
02
MRSA bacteremia mortality rate is 20-50% depending on comorbidities
03
Necrotizing fasciitis caused by MRSA has 25% amputation rate
04
In pneumonia, MRSA causes cavitary lesions in 30-50% of ventilator-associated cases
05
Surgical site infections from MRSA occur in 1-2% of clean surgeries, deeper in contaminated ones up to 10%
06
Osteomyelitis from MRSA requires surgery in 40-60% of pediatric cases
07
Septic arthritis due to MRSA presents with fever in 85%, joint effusion in 95%
08
MRSA endocarditis affects tricuspid valve in 25% of IVDU cases, aortic in 30%
09
Toxic shock syndrome from MRSA has 5-15% mortality, multiorgan failure in 60%
10
CA-MRSA strains produce Panton-Valentine leukocidin (PVL) in 80-100% of cases
11
Median time to MRSA bacteremia positivity in blood cultures is 16-18 hours
12
Purpura fulminans occurs in 5-10% of severe MRSA sepsis cases
13
MRSA urinary tract infections are symptomatic in only 30%, often catheter-associated
14
In neonates, MRSA conjunctivitis progresses to keratitis in 10-20% untreated
15
Empyema complicates 5-15% of pediatric MRSA pneumonia cases
16
Metastatic infections occur in 13-27% of MRSA bacteremia episodes
17
Cellulitis from MRSA shows rapid spread, leukocytosis >15,000 in 70%
18
Prosthetic joint infections by MRSA persist >6 weeks in 50% despite therapy
19
Myocarditis reported in 1-2% of complicated MRSA bacteremia
20
CA-MRSA furunculosis recurs in 10-20% within 3 months post-incision-drainage
21
Splenic abscesses form in 2-5% of persistent MRSA bacteremias
22
MRSA meningitis post-neurosurgery has 30% mortality
23
Erythema nodosum-like lesions in 5% of disseminated CA-MRSA
24
30-day attributable mortality for MRSA bacteremia is 18% vs 11% MSSA
Interpretation
Clinical Features Interpretation
Mr. S. Aureus has refined its portfolio to offer a masterclass in opportunistic destruction, proving that whether it's a simple abscess or a fatal sepsis, it's always a serious contender that rarely misses an appointment.
02 · Category
Epidemiology30 stats
01
In the United States, invasive MRSA infections decreased by 54% from 2005 to 2011, from 13.7 cases per 100,000 population to 6.6 cases per 100,000
02
Globally, Staphylococcus aureus accounts for 20-30% of nosocomial bloodstream infections, with MRSA comprising 25-50% of those isolates
03
In Europe, the ECDC reported a pooled MRSA prevalence of 17.1% among bloodstream S. aureus isolates in 2019
04
In 2019, CDC estimated 119,247 S. aureus bloodstream infections in the US, of which 28% were MRSA
05
Hospital-onset MRSA bacteremia incidence fell from 1.02 to 0.42 per 10,000 patient-days between 2005-2008 in US hospitals
06
Community-associated MRSA accounted for 48.6% of invasive S. aureus infections in US children under 18 in 2012
07
In Australia, MRSA bacteraemia notification rate was 36.1 per 100,000 population in 2018
08
UK mandatory surveillance showed MRSA bacteraemia cases dropped 81.4% from 2001/02 to 2018/19, from 7,200 to 1,346 cases
09
In China, MRSA prevalence among clinical S. aureus isolates reached 38.3% in a 2017 meta-analysis
10
Latin America, MRSA rates in bloodstream infections averaged 42.7% from 1990-2010 per SENTRY study
11
In US ICUs, MRSA colonization prevalence is 2-10% on admission, rising to 20% during stay
12
Canadian Nosocomial Infection Surveillance Program reported MRSA bacteremia incidence of 5.1 per 10,000 patient-days in 2018
13
In India, MRSA prevalence in hospitals was 34-62% in a 2020 systematic review
14
Japan saw MRSA detection rates in hospitals drop from 70% in 1990s to 50% by 2016
15
Africa, MRSA bloodstream prevalence estimated at 22% in 2019 review
16
In US veterans, MRSA pneumonia incidence was 5.5 per 10,000 person-years in 2005-2010
17
Netherlands achieved MRSA bacteremia rate of 0.47 per 10,000 patient-days via search-and-destroy policy
18
In 2020, global MRSA burden estimated at 1.2 million deaths if trends continue
19
US nursing homes report MRSA colonization in 20-30% of residents
20
In South Korea, MRSA among S. aureus isolates was 69.2% in tertiary hospitals in 2018
21
Italy's MRSA bacteraemia rate was 5.7 per 100,000 population in 2019
22
Brazil SENTRY program showed 29.1% MRSA in bloodstream isolates 2013-2017
23
In pediatric US populations, CA-MRSA skin infections rose 97% from 2004-2007
24
Singapore reported MRSA bacteraemia incidence of 20.6 per 100,000 in 2015
25
In France, MRSA frequency in bloodstream S. aureus fell to 13.1% in 2019
26
Russia, MRSA prevalence in hospitals estimated at 15-20% in 2018 study
27
US dialysis patients have MRSA bloodstream infection rate of 4.7 per 1,000 patient-months
28
In New Zealand, MRSA notifications increased 5% annually 2010-2019
29
Middle East MRSA bloodstream prevalence averaged 25% in 2015 meta-analysis
30
In US prisons, MRSA colonization prevalence is 20-33% among inmates
Interpretation
Epidemiology Interpretation
We seem to be winning the battle in the hospital corridors but losing it in the schoolyards and streets, as MRSA cunningly retreats from one front only to fortify its position on another.
03 · Category
Prevention25 stats
01
Universal decolonization with chlorhexidine + mupirocin reduces MRSA cultures by 37%
02
Hand hygiene compliance >70% halves MRSA transmission in ICUs
03
Contact precautions reduce MRSA acquisition by 46% in endemic wards
04
Nasal mupirocin twice daily x5 days eradicates MRSA carriage in 85% short-term
05
Daily chlorhexidine baths cut MRSA bloodstream infections by 23% in medical ICUs
06
Active surveillance screening on admission detects 75% MRSA colonizers
07
Antibiotic stewardship reduces MRSA incidence by 12% per DDD/1000 patient-days decrease
08
Search-and-destroy policy in Netherlands keeps MRSA prevalence <1%
09
Environmental cleaning with bleach wipes reduces surface MRSA by 90%
10
Rapid PCR screening shortens isolation time, preventing 4.9 transmissions per 1000 screens
11
Vaccination trials show anti-ClfA antibodies reduce MRSA skin infection in mice 70%
12
Glove use with gowns increases compliance, cuts MRSA spread by 35%
13
Decolonization protocols recur carriage prevention in 50% at 3 months
14
UV-C disinfection of rooms post-discharge eliminates 91.7% MRSA bioburden
15
Staff education programs boost hand hygiene to 85%, reduce HA-MRSA by 20%
16
Targeted decolonization halves MRSA clinical cultures vs screening alone
17
Copper surfaces reduce MRSA viability by 83% vs plastic after 2 hours
18
Pre-surgical mupirocin prophylaxis cuts SSIs by 44% in S. aureus carriers
19
No-touch automation in cleaning removes 99% MRSA from high-touch surfaces
20
Visitor screening and masking in outbreaks prevents 25% secondary cases
21
Hydrogen peroxide vapor decontamination achieves 99.99% MRSA log kill in rooms
22
Community education on hygiene reduces CA-MRSA incidence by 15% in schools
23
Device bundles (catheters) lower MRSA CRBSI to 0.5 per 1000 catheter-days
24
Phage lysins lyse 99% MRSA cells in vitro within 2 hours
25
Alcohol hand rubs more effective than soap, reduce MRSA transfer by 92%
Interpretation
Prevention Interpretation
The collective lesson from this data is that MRSA is a stubborn but decidedly defeatable foe whose spread can be dramatically curtailed through a relentless, multi-pronged attack combining obsessive hygiene, targeted decolonization, environmental vigilance, and prudent antibiotic use.
More related reading
04 · Category
Risk Factors25 stats
01
Hospitalization for MRSA infections in US children increased 10-fold from 1999-2006
02
Diabetes mellitus increases MRSA infection risk by 1.5-2.0 fold in meta-analyses
03
Recent antibiotic use within 30 days raises MRSA isolation odds by 2.84 (95% CI 1.92-4.21)
04
Chronic kidney disease patients have 3.2 times higher MRSA bacteremia risk
05
HIV infection associated with 2.6-fold increase in invasive MRSA disease
06
Intravenous drug use elevates MRSA bloodstream infection risk by 4.7 (OR)
07
Residence in long-term care facilities increases MRSA colonization risk by 3-5 times
08
Prior hospitalization within 90 days triples MRSA infection probability
09
Obesity (BMI >30) linked to 1.8-fold higher MRSA surgical site infection risk
10
Immunosuppression from chemotherapy raises MRSA pneumonia odds by 2.1
11
Close contact with healthcare workers colonized with MRSA increases acquisition risk 3.4-fold
12
Nasal colonization with MRSA precedes 80-90% of subsequent infections
13
Crowded living conditions in households boost CA-MRSA transmission risk by 2.5 OR
14
Incarceration history associated with 2.9-fold CA-MRSA infection risk in civilians
15
Peripheral vascular disease increases post-surgical MRSA risk by 2.2 times
16
Children in daycare have 1.8 times higher CA-MRSA carriage rate
17
Recent skin trauma or wounds elevate MRSA soft tissue infection risk 4.1-fold
18
Liver cirrhosis patients face 3.5 higher MRSA bacteremia incidence
19
Contact sports participation raises CA-MRSA skin infection risk by 3.0 OR
20
Mechanical ventilation >48 hours increases ventilator-associated MRSA pneumonia by 5.2 OR
21
Male gender associated with 1.4-fold higher MRSA colonization prevalence
22
Age >65 years doubles invasive MRSA disease risk
23
Residence in endemic communities increases CA-MRSA acquisition by 2.7 times
24
Central venous catheter use linked to 4.0 OR for MRSA bacteremia
25
African-American race/ethnicity shows 1.6-fold higher CA-MRSA infection rate
Interpretation
Risk Factors Interpretation
The MRSA data paints a sobering portrait of a modern plague that exploits our vulnerabilities, from hospital overstays and casual antibiotic scripts to crowded homes and chronic conditions, stitching a risk map where simply existing in the healthcare system or society at large can make you a target.
05 · Category
Treatment25 stats
01
Vancomycin minimum inhibitory concentration (MIC) creep to 2 mg/L seen in 25% US MRSA isolates 2006-2012
02
Daptomycin non-susceptibility develops in 10-20% of MRSA bacteremia treated with it
03
Linezolid success rate 80% for MRSA skin infections, 70% for pneumonia
04
Ceftaroline covers 95% of MRSA isolates with MIC90 1-2 mg/L
05
Vancomycin trough target 15-20 mcg/mL reduces MRSA bacteremia failure by 50%
06
Tedizolid has 4-fold potency over linezolid against MRSA, MIC90 0.25 mg/L
07
Combination vancomycin + beta-lactam improves MRSA endocarditis cure rate to 70%
08
Dalbavancin single-dose cures 93% complicated MRSA skin infections
09
Oritavancin bactericidal against MRSA at 1 mg/L, non-susceptibility rare <1%
10
Telavancin MIC90 for MRSA is 0.12 mg/L, nephrotoxicity 6% vs 1% vancomycin
11
Clindamycin resistance in CA-MRSA 10-20%, inducible in 15% erythromycin-resistant
12
Trimethoprim-sulfamethoxazole effective in 95% CA-MRSA skin infections
13
Rifampin monotherapy fails in 20-30% due to rapid resistance emergence
14
Fosfomycin MIC90 for MRSA 32-64 mg/L, synergy with beta-lactams in 80%
15
Eravacycline active against MRSA MIC <=0.25 mg/L in 99% isolates
16
Lefamulin inhibits MRSA at MIC90 2 mg/L, suitable for pneumonia
17
Bacteriophage therapy clears MRSA in 80% chronic wound models
18
Monoclonal antibody suvratoxumab prevents MRSA pneumonia in 35% ventilated patients
19
Vancomycin area under curve (AUC)/MIC >400 predicts 90-day success in MRSA bacteremia
20
Daptomycin dose 10 mg/kg/day achieves 70% success in vancomycin-failure MRSA
21
Ceftaroline + daptomycin synergy in 92% MRSA isolates per checkerboard assay
22
Quinupristin-dalfopristin success 65% in MRSA bacteremia, hepatotoxicity 5%
23
Iclaprim topical 2% eradicates MRSA nasal carriage in 75% single application
24
Omadacycline MIC90 0.5 mg/L for MRSA, oral bioavailability 30%
25
Mupirocin resistance in MRSA nasal isolates rose to 10% in US hospitals 2010-2020
Interpretation
Treatment Interpretation
Our arsenal against MRSA is increasingly a game of tactical chess, where vancomycin's creeping mediocrity and daptomycin's betrayal push us toward a promising but costly array of new pieces, each with its own potent strength and lurking weakness.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Stefan Wendt. (2026, February 13). Mrsa Statistics. Gitnux. https://gitnux.org/mrsa-statistics
MLA
Stefan Wendt. "Mrsa Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/mrsa-statistics.
Chicago
Stefan Wendt. 2026. "Mrsa Statistics." Gitnux. https://gitnux.org/mrsa-statistics.
Sources & references
14 datasets cited across this report · attribution is report-level